[Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma] NLM AIDSLINE Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


[Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma]

Wien Klin Wochenschr. 1987 Feb 20;99(4):120-3. Unique Identifier : AIDSLINE MED/87207995
Steger G; Dittrich C; Eichler HG; Flener R; Moser K

Abstract: Two patients with AIDS and histologically confirmed Kaposi's sarcoma were treated with 3 X 10(6) U/m2 interferon alpha 2C (rIFN alpha 2C) subcutaneously three times a week. In both cases remissions (7 weeks and more than 9 months) of the tumour lesions were achieved and in one case pretherapeutic moderate thrombocytopenia improved. The positive serum antibody titres to HTLV III-virus showed no conversion. Except for fever (below 39 degrees C) during the first two weeks of IFN treatment in both patients, therapy-requiring hypotonia, mild depression, leucopenia (WHO grade 1) and thrombocytopenia (WHO grade 2) in one patient, no side effects were observed. All the above-mentioned features were reversible after termination of treatment. Further studies to optimize the dosage of rIFN alpha 2C and its time schedule in the treatment of Kaposi's sarcoma in patients with AIDS are recommended.
Keywords: Acquired Immunodeficiency Syndrome/*THERAPY Adult Case Report Dose-Response Relationship, Drug English Abstract Homosexuality Human Interferon Type I/*THERAPEUTIC USE Male Recombinant Proteins/*THERAPEUTIC USE Sarcoma, Kaposi's/*THERAPY Skin Neoplasms/*THERAPY JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/KWDtherapyadultcasereportdose-responserelationship,drugenglishabstracthomosexualityhumaninterferontypei/KWDtherapeuticusemalerecombinantproteins/KWDtherapeuticusesarcoma,kaposi's/KWDtherapyskinneoplasms/KWDtherapyjournalarticle
870830
M8780226

Copyright © 1987 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .